Curated News
By: NewsRamp Editorial Staff
March 13, 2026
Tonix Launches First New Fibromyalgia Drug in 15 Years, Reports Strong 2025 Results
TLDR
- Tonix Pharmaceuticals gains market advantage with TONMYA, the first new fibromyalgia treatment in 15 years, showing strong early adoption by over 1,500 healthcare providers.
- Tonix Pharmaceuticals launched FDA-approved TONMYA in November 2025, advanced pipeline programs including TNX-4800 for Lyme disease, and maintains $207.6 million cash to fund operations through early 2027.
- Tonix Pharmaceuticals' new fibromyalgia treatment TONMYA improves patient care while pipeline programs address major depressive disorder, Lyme disease, and rare diseases like Prader-Willi syndrome.
- Tonix Pharmaceuticals developed the first new fibromyalgia medicine in over 15 years while working on Lyme disease prevention and treatments for rare genetic disorders.
Impact - Why it Matters
This development matters significantly because fibromyalgia affects millions of people worldwide who have had limited treatment options for over a decade and a half. The approval and successful launch of TONMYA provides new hope for patients suffering from this chronic pain condition that often severely impacts quality of life. Beyond the immediate benefit to fibromyalgia patients, Tonix's robust pipeline addressing major depressive disorder, Lyme disease prevention, Prader-Willi syndrome, and transplant rejection represents potential breakthroughs across multiple areas of high unmet medical need. The company's strong financial position ensures continued research and development that could lead to additional therapeutic innovations, while the growing prescriber and patient adoption of TONMYA demonstrates real-world validation of this medical advancement. For investors and the broader healthcare community, Tonix's progress signals meaningful innovation in central nervous system and immunology treatments that could transform patient care across multiple conditions.
Summary
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company, has announced its fourth quarter and full year 2025 financial results, marking a pivotal moment with the successful U.S. launch of TONMYA™. This groundbreaking medicine represents the first new treatment approved for fibromyalgia in over 15 years, receiving FDA approval in August 2025 and becoming commercially available by prescription on November 17, 2025. Early launch metrics are highly promising, with more than 1,500 healthcare providers already prescribing the therapy and approximately 2,500 patients initiating treatment, signaling strong market acceptance for this long-awaited therapeutic advancement.
The company's progress extends beyond its flagship product, as Tonix Pharmaceuticals also advanced several key pipeline programs throughout 2025. Notably, the company in-licensed TNX-4800 for the seasonal prevention of Lyme disease and received Investigational New Drug clearance for the HORIZON Phase 2 study of TNX-102 SL for major depressive disorder. The company's development pipeline spans immunology and rare disease programs, including TNX-2900 for Prader-Willi syndrome and TNX-1500 for preventing kidney transplant rejection. With approximately $207.6 million in cash and cash equivalents at year-end, Tonix has substantial financial resources to support operations into the first quarter of 2027 while continuing to maximize the science behind TONMYA through additional clinical trials for major depressive disorder and acute stress disorder.
This news release was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio that focuses on biotechnology and life sciences sectors. BioMedWire provides comprehensive distribution services including wire solutions via InvestorWire, article syndication to over 5,000 outlets, enhanced press release features, and social media distribution through IBN to millions of followers. The platform serves as a crucial conduit for companies like Tonix Pharmaceuticals to reach investors, influencers, consumers, and journalists, ensuring maximum visibility for significant developments in the biomedical field. For those interested in following Tonix's progress, the latest news and updates relating to TNXP are available in the company's newsroom, providing ongoing access to important developments from this innovative biotechnology firm.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Launches First New Fibromyalgia Drug in 15 Years, Reports Strong 2025 Results
